Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kevin Grogan

Managing Editor

London, UK
Advertisement
Set Alert for Articles By Kevin Grogan

Latest From Kevin Grogan

Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan

Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.

Deals M & A

New Drugs Shine But Biosimilars Blunt Roche Revenue Rise

MabThera revenues sink 16% in Europe as the first biosimilars make in-roads into the market but the Swiss major is encouraged by another stellar performance from new MS drug Ocrevus.

Biosimilars Sales & Earnings

Silence Seeks Share Of Alnylam RNAi Success In Legal Action

The UK firm believes its siRNA stabilisation chemistryis represented in several late-stage RNAi studies and that market leader Alnylam requires a license that could have a material impact on Silence's market capitalization.

Intellectual Property Commercial

Consolidation in Generics Sector As Impax Merges With Amneal

The deal will create the fifth-largest generics company in the US with one of the largest pipelines, with about 150 pending ANDAs and 165 projects in active stages of development.

M & A Generic Drugs

Roche Goes Back To Nature With Warp Drive Antibiotic Pact

The Swiss major is paying up to $387m to get access to potential natural antibiotics that have not been analyzed previously, 'owing to historical technology limitations.'

Infectious Diseases Research & Development

European Approval Recommendation Delayed Again For Roche’s Ocrevus

No European approval recommendation for Roche multiple sclerosis drug Ocrevus but the Swiss major tells Scrip it is hopeful of getting approval within four months.

Neurology Drug Review
See All
Advertisement
UsernamePublicRestriction

Register